US President Donald Trump has announced plans for the distribution of 150 million rapid Covid-19 tests in the weeks to come. This announcement is aimed at reopening the economy. Out of the 150 million tests, 50 million tests will be allocated for vulnerable communities, including nursing homes; assisted living facilities, and health and hospice care agencies. The rapid tests give results in 15 minutes.
Hologic’s Panther Fusion SARS-CoV-2 assay has secured Emergency Use Authorization (EUA) from the US Food and Drug Administration for the testing of individuals showing no symptoms or other reasons to suspect Covid-19 19 infection. The high-throughput molecular diagnostic test is specifically authorised for screening asymptomatic people.
Quotient Limited has received EUA from the US FDA for its Covid-19 antibody test, which can identify antibodies produced in humans in response to the SARS-CoV-2 virus. This test uses Quotient's proprietary MosaiQ blood testing microarray technology. It CE mark on 1 May and is now available in both Europe and the US.
India’s CRISPR ‘Feluda’ Covid-19 test is claimed to be more accurate than a rapid antigen test and almost as quick, reported the Press Trust of India. It alters colour on identification of the SARS-CoV-2 virus and is claimed to be cheaper option than RT-PCR diagnosis.